Proactive Investors - Run By Investors For Investors

Futura Medical passes major milestone as it doses first patient in phase III study

MED2002 is being developed as a rapid onset version of pills such as Viagra and Cialis
couple in bed
An earlier phase II assessment of Futura’s glyceryl trinitrate proved its efficacy, safety and a rapid speed of onset

Futura Medical PLC (LON:FUM) said it has dosed the first patient in its phase III clinical study of MED2002, a gel used to treat erectile dysfunction.

Headline data from the trial is expected next year. MED2002 is being developed as a rapid onset version of pills such as Viagra and Cialis. It works without side-effects such as headaches.

WATCH: Futura Medical doses first patient in phase III study

An earlier phase II assessment of Futura’s glyceryl trinitrate proved its efficacy, safety and a rapid speed of onset.

Randomised study

The current study is a randomised, double-blind and placebo-controlled, which means half the trial group receive a substance with no therapeutic value.

Only at the end of the assessment will researchers know which cohort received the active gel.

Different doses of MED2002 will be used to find the optimum application.

Chief executive James Barder said the enrolment of the first person to the phase III study was a “major milestone”.

"Futura is now in a position to build value by progressing the development of MED2002 through its planned phase III studies, and we are excited to be moving closer to bringing an innovative, highly differentiated ED [erectile dysfunction] product to market that could help the many ED patients whose needs are not met by current treatments."

 

View full FUM profile View Profile

Futura Medical PLC Timeline

Newswire
December 17 2018

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use